The Public Utilities Commission of Ohio (PUCO) has rejected a bid from Amazon, Google, and several other major data center developers to nix American Electric Power’s (AEP) recently approved rate ...

Dominion Energy is proposing a rate increase for residential customers that will add $10.51 a month starting in 2027. The State Corporation Commission, which held its first hearing about the possible ...

COLUMBUS, Ohio (WCMH) — The Public Utilities Commission of Ohio rejected a bid from Amazon, Google and others to overturn AEP’s new tariff, or rate structure, specifically for data centers. Amazon and ...

A galaxy proto-supercluster was discovered using VIMOS instrument of ESO’s Very Large Telescope. The astronomers who discovered it have nicknamed the bohemoth “Hyperion.” It has been visualized here.

“We will have it on the President’s desk before Thanksgiving,” Lummis said during a conversation at the SALT conference in Jackson Hole, Wyoming on Wednesday. She previously said she expected ...

More cabins and buildings at Camp Mystic — the tragic site of more than two dozen deaths in the Texas flood — were at risk of flooding than what the federal government had previously reported, ...

The Eclipse Foundation's Jakarta EE Working Group has released Jakarta EE 11, the latest version of its enterprise Java platform, marking a significant step in modernizing enterprise Java development ...

The U.S. Senate took the initial steps toward final approval of its first major crypto legislation as members opened voting Wednesday on the bill to set standards for U.S. stablecoin issuers, clearing ...

Today, a brief rundown of news involving Insmed and Recursion Pharmaceuticals, as well as updates from Odyssey Therapeutics, Gilead Sciences and Novo Nordisk that you may have missed. Versant Ventures ...

(RTTNews) - Recursion Pharmaceuticals, Inc. (RXRX), a clinical-stage TechBio company, on Monday, announced that it is deprioritizing three of its clinical programs and one preclinical program ...

AI drug discovery specialist Recursion Pharmaceuticals is shelving three of its most advanced drug prospects in an effort to cut costs following a merger last year. Alongside its latest quarterly ...